Daanish Shaikh, MD
Addiction Medicine · Gilbert, AZNPI 1902105588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 24.6% of the total. Reporting peaked in 2019 at $531 and has fallen 80.7% since, to $102 in 2025.
Across 16 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$184
- Braeburn Inc.$130
- Alkermes, Inc.$125
- Pfizer$120
- AbbVie$66
- Sunovion Pharmaceuticals Inc.$50
- plus $74 from 3 others
What the payments were for
- Food & beverage$72096%
- Education$304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $184 |
| Braeburn Inc. | 2 | $130 |
| Alkermes, Inc. | 1 | $125 |
| Pfizer | 1 | $120 |
| AbbVie(2 entities) | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Indivior Inc. | 1 | $28 |
| Viiv Healthcare Company | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- ARISTADA INITIO$125
- ELIQUIS$120
- BRIXADI$102
How this compares
$750 in reported general payments places this provider in the 70th percentile of 37 addiction medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $2,420 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Gilbert
- Wen Hui CaiTucson$111K
- Wendell PhillipsPhoenix$16K
- Steven LocnikarScottsdale$7K
- Rosekamal McKinneyGlendale$5K
- Gerald HarrisPeoria$5K
- J Carvel JacksonMesa$3K
- Scott HavensPhoenix$3K
- Robert HalliganPhoenix$1K
- Michael CarltonPhoenix$918
- Ehab AbdallahScottsdale$865
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.